Biomarker indicates which women are at risk for breast cancer recurrence after tamoxi
 

A biomarker reflecting expression levels of two genes in tumor tissue may be able to predict which women treated for estrogen-receptor (ER)-positive breast cancer should receive a second estrogen-blocking medication after completing tamoxifen treatment.

More...